Research programme: parasitic disease therapeutics - Drugs for Neglected Diseases initiative/GlaxoSmithKline/University of Dundee

Drug Profile

Research programme: parasitic disease therapeutics - Drugs for Neglected Diseases initiative/GlaxoSmithKline/University of Dundee

Latest Information Update: 03 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Drugs for Neglected Diseases Initiative Foundation; GlaxoSmithKline; University of Dundee
  • Class Antiparasitics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Chagas disease; Leishmaniasis

Most Recent Events

  • 27 Mar 2018 GlaxoSmithKline, Drugs for Neglected Diseases initiative and University of Dundee agree to co-develop therapeutics for Leishmaniasis and Chagas disease
  • 27 Mar 2018 Early research in Chagas' disease in United Kingdom, Switzerland (unspecified route)
  • 27 Mar 2018 Early research in Leishmaniasis in United Kingdom, United Kingdom, Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top